Canada's Drug Agency to Decide Mounjaro Public Coverage

Assessment Timeline

The federal agency's assessment of tirzepatide, marketed as Mounjaro by Eli Lilly, is in its final stages according to recent regulatory updates. Provincial health ministries across Canada are awaiting the recommendation to determine coverage policies for their respective drug formularies.

Current Market Position

Unlike Ozempic and Wegovy, which have established coverage patterns across Canadian provinces, Mounjaro remains largely private-pay or requires special authorization. The Drug Agency's recommendation could standardize access protocols nationwide.

Eli Lilly recently reduced Mounjaro prices by 20% in Canada, potentially improving the drug's cost-effectiveness profile for the assessment. Current retail prices range from $315 to $340 monthly at major pharmacy chains including Shoppers Drug Mart and Costco.

Provincial Implications

A positive recommendation would trigger coverage reviews in all provinces, though implementation timelines vary by jurisdiction. Ontario typically implements Drug Agency recommendations within 90 days, while other provinces like British Columbia and Alberta may take longer to update their formularies.

The decision comes as provinces grapple with rising costs for GLP-1 medications. Recent data shows Canadian health plans spent over $3.5 billion on semaglutide products in 2025, with insurance coverage patterns varying significantly across the country.

Generic Competition Context

While Mounjaro faces potential coverage expansion, the semaglutide market prepares for generic competition. Health Canada continues reviewing nine applications for generic semaglutide, expected to launch later this year through companies including Sandoz, Teva, and Aspen Pharmacare.

Patients can track generic approvals through our generic semaglutide tracker and find answers to coverage questions in our FAQ section.

Market Access Timeline

Industry observers expect the Drug Agency announcement by early April 2026. Positive recommendations typically include specific patient criteria and monitoring requirements that provinces adopt into their coverage policies.

The assessment considers clinical evidence, cost-effectiveness data, and budget impact projections submitted by Eli Lilly. Provincial drug plans collectively serve over 30 million Canadians through various public insurance programs.